Press release MHRA approves GLP –one receptor agonist semaglutide to reduce possibility of significant coronary heart issues in obese or overweight Grown ups Semaglutide is the initial fat loss drug accredited in the UK like a preventative treatment method for the people with founded cardiovascular diseaseFrom setting ambitions to demystifying we